ArticlePloS one2025
Progression and natural history of Atypical Parkinsonism (ATPARK): Protocol for a longitudinal follow-up study from an underrepresented population.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role of DaT-SPECT Imaging in the Evaluation of Progressive Supranuclear Palsy.Life (Basel, Switzerland) · 2026Review
- Body Fluid-based Biomarkers for Cognitive Impairment in Parkinson's Disease.Annals of neurosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtypical Parkinsonian Syndromes (APS) form the third largest group of neurodegenerative disorders including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS). These conditions are characterized by rapid progression, poor prognosis, low survival rates, and limited treatment options. Few studies have suggested that genetic, environmental factors and inflammation contribute to the pathobiology of these complex disorders, however, the etiology of disease and progression remains unclear.
methodsA multicenter prospective longitudinal (3-time point) study will be conducted with a total sample size of 400 across all the groups (PSP, MSA, CBS). Patients with APS will be recruited after a detailed evaluation by movement disorder specialists and obtaining valid informed consent. The socio-demographic data and whole exome sequencing will be performed only at the baseline. Non-invasive procedures such as neurological and cognitive assessments, sleep quality assessments including polysomnography, brain imaging, and retinal imaging will be conducted at each time point. In addition, gene expressions, methylation patterns, inflammatory cytokines, disease-associated pathological proteins (Tau, pTau-181, α-synuclein and β-amyloid), non-targeted proteomics, skin biopsy, and iPSC will be performed at each time point eventually. The statistical analysis will be performed, followed by the developing of machine learning (ML) models. EXPECTED OUTCOMES AND
conclusionThis unique native dataset in APS will enhance our understanding of the molecular mechanisms driving pathological protein aggregation and disease progression. Furthermore, the longitudinal design of the study enables a detailed examination of symptom development, progression, and management. The ML models combined with advanced imaging techniques will aid in early diagnosis, differentiation among APS types, and the development of future clinical trials and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.